Oral broad spectrum antiviral TLR7 agonist for treatment of lassa fever
Ended Definitive Contract Awarded Last action
- Contract number
- HDTRA124C0014
- Awardee
-
Primmune Therapeutics, Inc. UEI RCE3KW671H83
- Awarding agency
-
Defense Threat Reduction Agency
Department of Defense
- Obligated
- $11,290,689
Award facts
- Opportunity
-
- Science and Technology New Initiatives BAA Solicitation · HDTRA117S0002 · Posted Nov 2, 2016
- Contract value 49% obligated
-
- $11,290,689.18 Current, with exercised options
- $23,143,346.26 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Carlsbad, CA 92008, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $79,000 | |
| Funding Only Action | $217,509 | |
| Exercise an Option | $366,285 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,391,142 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,391,142 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $5,221,301 | |
| Funding Only Action | $1,778,699 | |
| Other Administrative Action | $0 | |
| Original award | $845,610 |
Show all 15
About this award
The Defense Threat Reduction Agency awarded a $23.1 million definitive contract to Primmune Therapeutics, Inc. for development of an oral broad spectrum antiviral TLR7 agonist for treatment of Lassa fever on January 30, 2024, under a cost-plus-fixed-fee pricing structure with no set-aside.
Place of performance is Carlsbad, California. The originating solicitation, a Broad Agency Announcement posted November 2, 2016, solicited innovative research and development projects focused on countering weapons of mass destruction across six technology areas at Technology Readiness Levels 2 through 6, accepting submissions on a rolling basis through October 2021. Work is scheduled for completion by December 31, 2027.
Quick answers
Who was awarded contract HDTRA124C0014?
HDTRA124C0014 was awarded to Primmune Therapeutics, Inc. by Defense Threat Reduction Agency (Department of Defense) on January 30, 2024.
How much is contract HDTRA124C0014 worth?
The government has obligated $11,290,689 on HDTRA124C0014. Its potential value, with all options, is $23,143,346.
Was contract HDTRA124C0014 competed?
The extent of competition for HDTRA124C0014 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award